Data gathered: November 27
AI Stock Analysis - Mannkind (MNKD)
Analysis generated September 9, 2024. Powered by Chat GPT.
Mannkind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. The company is especially known for its rapid-acting insulin, Afrezza, which is widely used to treat diabetes. Mannkind’s commitment to innovation and patient care has helped it carve out a niche within the competitive biopharmaceutical sector.
Stock Alerts - Mannkind (MNKD)
 |
Mannkind | November 26 Price is down by -5.7% in the last 24h. |
|
Mannkind | November 26 Insider Alert: Binder Steven B. is continuing selling shares |
|
Mannkind | November 20 Insider Alert: Binder Steven B. is selling shares |
|
Mannkind | November 15 Price is down by -5.3% in the last 24h. |
Alternative Data for Mannkind
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 16 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| Patents | 117 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 26 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,462 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,097 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 55 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 40,751 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,783 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 272 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 81 | Sign up | Sign up | Sign up |
| Linkedin Employees | 556 | Sign up | Sign up | Sign up |
About Mannkind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
| Price | $6.61 |
| Target Price | Sign up |
| Volume | 2,260,000 |
| Market Cap | $1.85B |
| Year Range | $4.05 - $7.44 |
| Dividend Yield | 0% |
| PE Ratio | 84 |
| Analyst Rating | 67% buy |
| Industry | Biotechnology |
In the news
 |
MannKind (NASDAQ:MNKD) Stock Rating Lowered by StockNews.comNovember 24 - ETF Daily News |
 |
Principal Financial Group Inc. Buys 134,937 Shares of MannKind Co. (NASDAQ:MNKD)November 24 - ETF Daily News |
|
MannKind (NASDAQ:MNKD) Raised to Buy at StockNews.comNovember 12 - ETF Daily News |
|
US Bancorp DE Invests $407,000 in MannKind Co. (NASDAQ:MNKD)November 12 - ETF Daily News |
|
MannKind Co. (NASDAQ:MNKD) Given Average Recommendation of “Buy” by BrokeragesNovember 10 - ETF Daily News |
 |
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...November 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 68M | 27M | 41M | 12M | 15M | 0.000 |
| Q2 '24 | 66M | 30M | 36M | -2M | 6.1M | -0.010 |
| Q1 '24 | 65M | 28M | 38M | 11M | 15M | 0.040 |
| Q4 '23 | 53M | 28M | 25M | 1.4M | 6.9M | 0.004 |
| Q3 '23 | 51M | 28M | 23M | 1.7M | 5.7M | 0.010 |
Insider Transactions View All
| Binder Steven B. filed to sell 1,075,026 shares at $6.9. November 25 '24 |
| Binder Steven B. filed to sell 1,075,026 shares at $6.8. November 19 '24 |
| Tross Stuart A filed to sell 967,191 shares at $7.3. November 8 '24 |
| Tross Stuart A filed to sell 1,022,191 shares at $6.3. September 4 '24 |
| Tross Stuart A filed to sell 1,047,191 shares at $6.3. August 30 '24 |
Similar companies
Read more about Mannkind (MNKD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Mannkind?
The Market Cap of Mannkind is $1.85B.
What is Mannkind's PE Ratio?
As of today, Mannkind's PE (Price to Earnings) ratio is 84.
What is the current stock price of Mannkind?
Currently, the price of one share of Mannkind stock is $6.61.
How can I analyze the MNKD stock price chart for investment decisions?
The MNKD stock price chart above provides a comprehensive visual representation of Mannkind's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Mannkind shares. Our platform offers an up-to-date MNKD stock price chart, along with technical data analysis and alternative data insights.
Does MNKD offer dividends to its shareholders?
As of our latest update, Mannkind (MNKD) does not offer dividends to its shareholders. Investors interested in Mannkind should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Mannkind?
Some of the similar stocks of Mannkind are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.